Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Capital Expenditures data on file, last reported at $2.5 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $2.5 million, down 51.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (up 67.23% YoY), and the FY2025 annual result was $9.5 million, up 697.15% from the prior year.
• Capital Expenditures rose to $2.5 million in Q1 2026 per DNLI's latest filing, from $1.5 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $6.8 million in Q2 2022 and troughed at -$11.5 million in Q4 2022.
• A 5-year average of $1.6 million and a median of $2.5 million in 2026 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 5228.95% in 2023, then tumbled 530.78% in 2024.
• A 5-year view of Capital Expenditures shows it stood at -$11.5 million in 2022, then jumped by 119.4% to $2.2 million in 2023, then plunged by 530.78% to -$9.6 million in 2024, then soared by 115.83% to $1.5 million in 2025, then jumped by 61.81% to $2.5 million in 2026.
• Business Quant data shows DNLI's Capital Expenditures at $2.5 million in Q1 2026, $1.5 million in Q4 2025, and -$1.4 million in Q3 2025.